HOME > Upside in Decelerating Gx Arena
Upside in Decelerating Gx Arena
-
In Authorized Generic Spree, Daiichi Sankyo Espha Focuses More on “Popularization” than “Sales” When It Comes to Cancer AGs
April 24, 2019
-
Nihon Generic to Mount Aggressive Sales Campaigns Taking Advantage of Group Synergy
April 16, 2019
-
Meiji Pharma Pursuing Low-Cost Strategy to Weather Storm in Generics Space, Overseas Plants Hold Key
March 11, 2019
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…